论文部分内容阅读
应用聚合酶链反应（PCR）的方法，扩增CR1结构基因中发生突变包括一个内含子在内的约1．8kb的基因片段，结合HindⅢ酶切分析（RFLP），对肺癌患者红细胞CR1密度相关基因多态性进行了实验研究，同时利用红细胞C3b受体花环和免疫复合物（IC）花环法测定了CR1的活性。结果表明肺癌患者红细胞CR1密度相关基因型明显不同于正常人，且CR1的活性明显低于正常人（P＜0．01）。因此作者认为红细胞CR1密度相关基因型的改变可能是肺癌的易患因素之一。
A polymerase chain reaction (PCR) method was used to amplify a gene fragment of approximately 1.8 kb including an intron in the CR1 structural gene, bind HindIII digestion analysis (RFLP), and determine the red cell CR1 density in lung cancer patients. The polymorphisms of the related genes were studied experimentally, and the activity of CR1 was determined using the erythrocyte C3b receptor rosette and the immune complex (IC) rosette method. The results showed that the CR1 density-associated genotypes of erythrocytes in patients with lung cancer were significantly different from those in healthy individuals, and the activity of CR1 was significantly lower than that in normal subjects (P<0.01). Therefore, the author believes that changes in the RBC density-related genotype may be one of the risk factors for lung cancer.